'''Imepitoin''' ({{abbrlink|INN|International Nonproprietary Name}}), sold under the brand name '''Pexion''', is an [[anticonvulsant]] which is used in [[veterinary medicine]] in [[Europe]] to treat [[epilepsy]] in dogs.<ref name="pmid24357084">{{cite journal | vauthors = Rundfeldt C, Löscher W | title = The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy | journal = CNS Drugs | volume = 28 | issue = 1 | pages = 29–43 | year = 2014 | pmid = 24357084 | doi = 10.1007/s40263-013-0129-z | url = }}</ref><ref name="Sanders2015">{{cite book|author=Sean Sanders|title=Seizures in Dogs and Cats|url=https://books.google.com/books?id=BoXgCAAAQBAJ&pg=PA209|date=29 April 2015|publisher=Wiley|isbn=978-1-118-68970-7|pages=209–}}</ref><ref name="DeweyCosta2015">{{cite book|author1=Curtis W. Dewey|author2=Ronaldo C. da Costa|title=Practical Guide to Canine and Feline Neurology|url=https://books.google.com/books?id=JSWJCgAAQBAJ&pg=PT806|date=8 September 2015|publisher=Wiley|isbn=978-1-119-06204-2|pages=806–}}</ref><ref name="Drugs.com">https://www.drugs.com/international/imepitoin.html</ref> It is not approved in the [[United States]].<ref name="Sanders2015" /><ref name="DeweyCosta2015" /><ref name="Drugs.com" /> The drug also has [[anxiolytic]] effects.<ref name="pmid24357084" /><ref name="Sanders2015" /> It was originally developed to treat epilepsy in humans, but [[clinical trial]]s were terminated upon findings of unfavorable [[metabolism|metabolic]] differences in [[smoking|smoker]]s and non-smokers.<ref name="pmid24357084" /><ref name="Sanders2015" />
